Navigation Links
Okyanos Heart Institute’s Chief Medical Officer Speaks at ACC’s Scientific Session

FREEPORT, The Bahamas (PRWEB) February 28, 2013

Okyanos Heart Institute, which brings a new standard of care and better quality of life to patients with chronic coronary artery disease using cardiac stem cell therapy, announces that Chief Medical Officer Howard Walpole Jr., M.D., MBA, FACC, FACAI will speak at The American College of Cardiology’s (ACC’s) 13th Annual Scientific Session. Dr. Walpole will join a panel of experts on the topic of “Readmission Reduction: Why Should You Care?” The session features thought leaders who will provide the latest data on successful readmission strategies. They will incorporate case studies and results from Medicare's recent test project, and an emphasis on care coordination with a proven track record in reducing readmissions in three index conditions: heart failure, acute myocardial infarction, and pneumonia. The session will be held from 12:30 p.m. to 1:45 p.m. on Sunday, March 10 at the Moscone Center in San Francisco.

“Readmissions for the three index conditions account for over $17 billion a year (in 2004) in health care expenses,” said Cathleen Biga, chief executive officer of Cardiovascular Management of Illinois (CMI) and the chair of the session. “Hospitals readmit nearly one in five Medicare patients within one month of discharge. Since October 1, 2012, over 2,200 hospitals are facing penalties (payment adjustments) totaling over $280 million, making this topic one of the most important, if not the most important topic of 2013.”

“I am looking forward to bringing this important discussion to the ACC conference,” said Walpole. “My topic in the discussion will be about reducing heart failure readmissions using a case study method to help participants through this transformative area of healthcare.”

More information about the event can be found at

Based in Freeport, The Bahamas, Okyanos Heart Institute adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, and a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac stem cell therapy. Okyanos Treatment utilizes cardiac stem cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. The treatment helps to facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, log on to

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Okyanos Heart Institute’s Chief Medical Officer To Speak At American College Of Cardiology Seminar In Florida
2. Witnessing, Experiencing Traumatic Events May Worsen Heart Disease
3. Risk of suicide and fatal heart attack immediately following a cancer diagnosis
4. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
5. In children born with severe heart defect, surgical management has little effect on neuro outcomes
6. Invasive heart test being dramatically overused, Stanford study shows
7. Heart failure patients with diabetes may benefit from higher glucose levels
8. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
9. EKG Heart Test May Predict Risk in Older Adults
10. Common Blood Pressure Drug Safe for Heart Failure: Study
11. Spouses of Cancer Patients May Have Raised Risk of Heart Disease, Stroke
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: